| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $39,659,460 | 40 | 100 |
| Heeson Lee | EVP, Head of Incyte Intl | 0 | $0 | 1 | $289,017 | $-289,017 |
| Tray Thomas | Principal Accounting Officer | 0 | $0 | 6 | $520,904 | $-520,904 |
| Mayes Patrick A | EVP & Chief Scientific Officer | 0 | $0 | 2 | $554,965 | $-554,965 |
| Iyengar Vijay K | EVP, GMAPPS | 0 | $0 | 3 | $736,698 | $-736,698 |
| Denton Sheila A. | EVP & General Counsel | 0 | $0 | 13 | $1.06M | $-1.06M |
| Issa Mohamed Khairie | EVP, Head of US Oncology | 0 | $0 | 1 | $1.18M | $-1.18M |
| CAGNONI PABLO J | President, R&D | 0 | $0 | 1 | $1.88M | $-1.88M |
| Flannelly Barry P | EVP & General Manager US | 0 | $0 | 4 | $2.26M | $-2.26M |
| Morrissey Michael James | EVP, Head of Tech. Operations | 0 | $0 | 2 | $5.68M | $-5.68M |
| Stein Steven H | EVP & Chief Medical Officer | 0 | $0 | 6 | $5.72M | $-5.72M |
| Hoppenot Herve | director | 0 | $0 | 1 | $19.77M | $-19.77M |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Over the last 12 months, insiders at Incyte Corporation have bought $0 and sold $39.66M worth of Incyte Corporation stock.
On average, over the past 5 years, insiders at Incyte Corporation have bought $129.13M and sold $12.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 84 shares for transaction amount of $6,044 was made by BAKER FELIX () on 2022‑03‑08.
| 2026-02-19 | Sale | CAGNONI PABLO J | President, R&D | 18,668 0.0092% | $100.91 | $1.88M | -1.44% | |
| 2026-01-07 | Sale | Issa Mohamed Khairie | EVP, Head of US Oncology | 10,856 0.0054% | $109.07 | $1.18M | -7.59% | |
| 2026-01-05 | Sale | Stein Steven H | EVP & Chief Medical Officer | 15,634 0.008% | $101.70 | $1.59M | +0.70% | |
| 2025-12-19 | Sale | Tray Thomas | Principal Accounting Officer | 2,774 0.0014% | $100.00 | $277,400 | -1.27% | |
| 2025-12-18 | Sale | Tray Thomas | Principal Accounting Officer | 600 0.0003% | $98.25 | $58,950 | +4.22% | |
| 2025-12-17 | Sale | Morrissey Michael James | EVP, Head of Tech. Operations | 4,323 0.0022% | $97.26 | $420,455 | +3.85% | |
| 2025-12-16 | Sale | Morrissey Michael James | EVP, Head of Tech. Operations | 54,008 0.0276% | $97.29 | $5.25M | +4.46% | |
| 2025-12-11 | Sale | Mayes Patrick A | EVP & Chief Scientific Officer | 255 0.0001% | $94.94 | $24,210 | +5.31% | |
| 2025-12-10 | Sale | Mayes Patrick A | EVP & Chief Scientific Officer | 5,553 0.0028% | $95.58 | $530,756 | +6.32% | |
| 2025-12-02 | Sale | Stein Steven H | EVP & Chief Medical Officer | 20,105 0.0103% | $102.51 | $2.06M | -0.52% | |
| 2025-12-01 | Sale | Stein Steven H | EVP & Chief Medical Officer | 2,559 0.0013% | $102.96 | $263,475 | -0.98% | |
| 2025-11-24 | Sale | Tray Thomas | Principal Accounting Officer | 600 0.0003% | $103.00 | $61,800 | -4.66% | |
| 2025-11-21 | Sale | Tray Thomas | Principal Accounting Officer | 169 <0.0001% | $102.00 | $17,238 | -0.69% | |
| 2025-11-17 | Sale | Denton Sheila A. | EVP & General Counsel | 278 0.0001% | $104.36 | $29,012 | -2.64% | |
| 2025-11-10 | Sale | Hoppenot Herve | director | 187,500 0.095% | $105.46 | $19.77M | -4.13% | |
| 2025-11-05 | Sale | Stein Steven H | EVP & Chief Medical Officer | 5,233 0.0029% | $102.20 | $534,813 | -3.73% | |
| 2025-11-04 | Sale | Denton Sheila A. | EVP & General Counsel | 598 0.0003% | $101.36 | $60,613 | -1.11% | |
| 2025-11-03 | Sale | Heeson Lee | EVP, Head of Incyte Intl | 3,074 0.0016% | $94.02 | $289,017 | +0.22% | |
| 2025-10-15 | Sale | Denton Sheila A. | EVP & General Counsel | 277 0.0001% | $85.13 | $23,581 | +15.02% | |
| 2025-10-03 | Sale | Denton Sheila A. | EVP & General Counsel | 3,501 0.0018% | $85.54 | $299,476 | +16.34% |
| Hoppenot Herve | director | 329646 0.1656% | $31.63M | 2 | 4 | +4.34% |
| CAGNONI PABLO J | President, R&D | 234800 0.118% | $22.53M | 0 | 1 | |
| Issa Mohamed Khairie | EVP, Head of US Oncology | 66132 0.0332% | $6.34M | 0 | 1 | |
| Mayes Patrick A | EVP & Chief Scientific Officer | 60011 0.0302% | $5.76M | 0 | 2 | |
| Iyengar Vijay K | EVP, GMAPPS | 40540 0.0204% | $3.89M | 0 | 19 | |
| Flannelly Barry P | EVP & General Manager US | 35149 0.0177% | $3.37M | 0 | 26 | |
| Stein Steven H | EVP & Chief Medical Officer | 34203 0.0172% | $3.28M | 0 | 21 | |
| Heeson Lee | EVP, Head of Incyte Intl | 29241 0.0147% | $2.81M | 0 | 1 | |
| Morrissey Michael James | EVP, Head of Tech. Operations | 27507 0.0138% | $2.64M | 0 | 3 | |
| Denton Sheila A. | EVP & General Counsel | 26569 0.0134% | $2.55M | 0 | 15 | |
| Tray Thomas | Principal Accounting Officer | 22973 0.0115% | $2.2M | 0 | 15 | |
| BAKER BROS. ADVISORS LP | 33039604 16.6016% | $3.17B | 11 | 0 | +3.8% | |
| BAKER JULIAN | director | 19757285 9.9276% | $1.9B | 8 | 0 | +17.75% |
| Baker Brothers Life Sciences Capital (GP), LLC | director, 10 percent owner | 12430783 6.2462% | $1.19B | 51 | 5 | +21.96% |
| Baker Biotech Capital (GP), LLC | director, 10 percent owner | 2933021 1.4738% | $281.39M | 43 | 5 | +21.05% |
| BAKER FELIX | 2926657 1.4706% | $280.78M | 1 | 0 | +8.15% | |
| TISCH THOMAS J | other | 1416661 0.7118% | $135.91M | 1 | 0 | +52.29% |
| TISCH ANDREW H | other | 1216661 0.6113% | $116.73M | 1 | 0 | +52.29% |
| TISCH JAMES S | other | 1216661 0.6113% | $116.73M | 1 | 0 | +52.29% |
| TISCH DANIEL R | other | 1216661 0.6113% | $116.73M | 1 | 0 | +52.29% |
| BAKER BIOTECH CAPITAL II GP LLC | 10 percent owner | 1091407 0.5484% | $104.71M | 2 | 0 | +39.59% |
| WHITFIELD ROY A | director | 621082 0.3121% | $59.59M | 0 | 22 | |
| 14159 capital (GP), LLC | director, 10 percent owner | 355839 0.1788% | $34.14M | 50 | 5 | +21.76% |
| FRIEDMAN PAUL A | director | 255531 0.1284% | $24.52M | 12 | 20 | +76.59% |
| Baker Bros. Capital (GP), LLC | director, 10 percent owner | 239258 0.1202% | $22.95M | 42 | 5 | +21.44% |
| BROOKE PAUL A | director | 196756 0.0989% | $18.88M | 3 | 2 | +3.81% |
| Baker / Tisch Capital (GP), LLC | director, 10 percent owner | 159739 0.0803% | $15.33M | 29 | 5 | +15.27% |
| Wenqing Yao | EVP, Head of Discovery Chem | 94080 0.0473% | $9.03M | 0 | 18 | |
| DE SCHUTTER RICHARD U | director | 92290 0.0464% | $8.85M | 2 | 6 | +19.56% |
| SWAIN PAULA J | EVP, Human Resources | 77530 0.039% | $7.44M | 1 | 39 | +27.11% |
| Pasquale Maria E | EVP & General Counsel | 68524 0.0344% | $6.57M | 0 | 11 | |
| METCALF BRIAN W | Chief Drug Discovery Scientist | 66504 0.0334% | $6.38M | 2 | 4 | +24.57% |
| Dhanak Dashyant | EVP & Chief Scientific Officer | 53263 0.0268% | $5.11M | 0 | 19 | |
| ARIKO BARRY A | director | 45834 0.023% | $4.4M | 0 | 3 | |
| Friedman Steven M. | EVP, Biology & Preclinical Dev | 38137 0.0192% | $3.66M | 0 | 1 | |
| Dickinson Jonathan Elliott | EVP, General Manager, Europe | 36390 0.0183% | $3.49M | 0 | 3 | |
| Huber Reid M | EVP, Chief Scientific Officer | 35183 0.0177% | $3.38M | 0 | 10 | |
| Trower Paul | Principal Accounting Officer | 32268 0.0162% | $3.1M | 0 | 14 | |
| Siegel Eric H. | EVP, General Counsel | 21733 0.0109% | $2.09M | 0 | 26 | |
| DIXON WENDY L | director | 17259 0.0087% | $1.66M | 1 | 5 | +44.82% |
| Levy Richard S | EVP, Chief Drug Dev Officer | 16926 0.0085% | $1.62M | 0 | 34 | |
| GRYSKA DAVID W | Executive Vice President, CFO | 10970 0.0055% | $1.05M | 0 | 7 | |
| BIENAIME JEAN JACQUES | director | 8646 0.0043% | $829,497.24 | 6 | 3 | <0.0001% |
| HASTINGS DAVID C | Chief Financial Officer | 8500 0.0043% | $815,490.00 | 3 | 8 | +39.74% |
| SCHRECK PATRICIA A | EVP, General Counsel | 4500 0.0023% | $431,730.00 | 2 | 4 | +35.88% |
| Daly James M | EVP, Chief Commercial Officer | 3521 0.0018% | $337,804.74 | 0 | 16 | |
| Chardonnet Laurent | 2905 0.0015% | $278,705.70 | 1 | 13 | +38.15% |
Incyte Corporation (INCY) | $961,890,236 | 276 | 22.46% | $19.09B |
$211,610,344 | 91 | 38.45% | $9.83B | |
$2,765,836 | 72 | 20.00% | $11.75B | |
$2,449,191,716 | 58 | 16.50% | $78.95B | |
$11,789,714 | 49 | 14.35% | $30.21B | |
$323,530,732 | 48 | 29.90% | $42.53B | |
$88,307,390 | 38 | -1.70% | $11.2B | |
$19,233,721 | 36 | 70.14% | $11.14B | |
$13,655,378 | 35 | 17.13% | $20.96B | |
$15,836,193 | 25 | 17.98% | $116B | |
$415,090,639 | 19 | -14.04% | $12.67B | |
$143,065,458 | 17 | 8.01% | $19.5B | |
$152,272,932 | 16 | -10.78% | $19.45B | |
$627,701,115 | 15 | 145.68% | $11.25B | |
$284,820 | 10 | 45.67% | $12.23B | |
$55,713,031 | 8 | -0.36% | $8.91B | |
$40,276,273 | 4 | 34.57% | $20.6B | |
$41,376,000 | 4 | -12.07% | $8.53B | |
$999,989 | 1 | 262.16% | $20.74B |
| Increased Positions | 515 | +77.56% | 16M | +8.12% |
| Decreased Positions | 291 | -43.83% | 14M | -6.83% |
| New Positions | 169 | New | 2M | New |
| Sold Out Positions | 52 | Sold Out | 2M | Sold Out |
| Total Postitions | 888 | +33.73% | 203M | +1.28% |
| Baker Bros. Advisors Lp | $3.12M | 15.69% | 30.74M | +388 | +<0.01% | 2025-09-30 |
| Vanguard Group Inc | $2.02M | 10.18% | 19.95M | -183,770 | -0.91% | 2025-09-30 |
| Blackrock, Inc. | $1.81M | 9.13% | 17.89M | -62,511 | -0.35% | 2025-09-30 |
| Dodge & Cox | $1.41M | 7.11% | 13.93M | -662,765 | -4.54% | 2025-09-30 |
| State Street Corp | $981,421.00 | 4.94% | 9.68M | -198,962 | -2.02% | 2025-09-30 |
| Aqr Capital Management Llc | $803,602.00 | 4.04% | 7.92M | -277,944 | -3.39% | 2025-09-30 |
| Renaissance Technologies Llc | $459,243.00 | 2.31% | 4.53M | +646,200 | +16.65% | 2025-09-30 |
| Geode Capital Management, Llc | $454,987.00 | 2.29% | 4.49M | +138,439 | +3.18% | 2025-09-30 |
| Lsv Asset Management | $404,270.00 | 2.03% | 3.99M | +124,266 | +3.22% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $314,802.00 | 1.58% | 3.1M | +373,298 | +13.67% | 2025-09-30 |